Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy

While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using pati...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Tao Wang, Desirée Denman, Silvia M. Bacot, Gerald M. Feldman
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Subjects:	immune checkpoint inhibitor anti-PD-(L)1 immunotherapy liquid biopsy biomarker PD-1 PD-L1
Online Access:	https://www.mdpi.com/2227-9059/10/5/1181